Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06460844 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
A Phase 1 study of Retinitis Pigmentosa and Choroideremia, sponsored by Ray Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 4
- Study locations
NCT06460844 is a Phase 1 study of Retinitis Pigmentosa and Choroideremia that is active but no longer recruiting, run by Ray Therapeutics. The registered enrollment target is 10 participants, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06460844, a Phase 1 study of Retinitis Pigmentosa and Choroideremia, is active but no longer recruiting, sponsored by Ray Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 18 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 4 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in the study eye at Visit 3 (Day 0) and be followed for a total of 5 years.
Conditions Studied
Interventions
- GENETIC RTx-015
Study Locations (4)
California
- Retina Vitreous Associates Medical Group - Beverly Hills
- UCI Alpha Clinic - Orange
Pennsylvania
- UPMC Vision Institute - Pittsburgh
Texas
- Retina Consultants of Texas Research Centers - Bellaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-08-27 |
| Est. Completion | 2030-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06460844
The ClinicalTrials.gov registry entry for NCT06460844 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (96% lower). The listed sponsor is Ray Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which RTx-015 is the first listed.
NCT06460844 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT06460844 about?
NCT06460844 is a clinical study titled "Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)". A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 18 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 4 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in...
What is the current status of trial NCT06460844?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-08-27. Estimated completion is 2030-10.
What conditions does trial NCT06460844 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa, Choroideremia.
What interventions are being tested in trial NCT06460844?
The interventions under investigation include: RTx-015 (GENETIC).
Who is sponsoring clinical trial NCT06460844?
This trial is sponsored by Ray Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06460844 being conducted?
This trial has 4 study locations across California, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
RECRUITING · Phase 1
-
BS01 in Patients With Retinitis Pigmentosa
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
ACTIVE NOT RECRUITING · Phase 1
-
CNS10-NPC for the Treatment of RP
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.